Target Audience (click to view)
This activity is designed to meet the needs of physicians and nurses.
Learning Objectives(click to view)
Upon completion of the educational activity, participants should be able to:
- Discuss the key findings of six studies presented at the 2017 American Academy of Allergy, Asthma & Immunology Annual Meeting.
Method of Participation(click to view)
Release Date: 5/12/2017
Expiration Date: 5/12/2018
Statements of credit will be awarded based on the participant reviewing monograph, correctly answer 2 out of 3 questions on the post test, completing and submitting an activity evaluation. A statement of credit will be available upon completion of an online evaluation/claimed credit form at https://lms.physiciansweekly.com/course/view.php?id=11. You must participate in the entire activity to receive credit. If you have questions about this CME/CE activity, please contact AKH Inc. firstname.lastname@example.org.
Credit Available(click to view)
CME Credit Provided by AKH Inc., Advancing Knowledge in Healthcare
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Physician’s Weekly’s. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is awarded 0.5 contact hours.
Commercial Support(click to view)
There is no commercial support for this activity.
Disclosures(click to view)
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.
Disclosure of Unlabeled Use & Investigational Product(click to view)
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer(click to view)
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.
Faculty & Credentials(click to view)
Complete the Post Test(click to view)
New research was presented at AAAAI 2017, the American Academy of Allergy, Asthma & Immunology Annual Meeting, from March 3 to 6 in Atlanta. The features below highlight some of the studies presented at the conference.
Maternal Vitamin E Levels & Asthma Risk
Previous research suggests there is a relationship between respiratory outcomes and isoforms of vitamin E, but little is known about the relationship between children’s risk for asthma and their mothers’ postpartum vitamin E levels. For a study, investigators examined data on more than 650 children with maternal postpartum plasma vitamin E isoforms measured at enrollment. Children and mothers were followed for the first 2 years of the child’s life. Children who wheezed were more likely to have mothers with significantly lower postpartum concentrations of vitamin E isoform alpha-tocopherol than those who did not wheeze. Children born to mothers with low vitamin E levels were also more likely to require asthma medication at 2 years.
Examining Disparities in Asthma Deaths
Previous studies indicate that African Americans experience a substantially higher rate of asthma-related mortality than Hispanics and Caucasians. Few studies have explored the reason(s) behind this disparity. Study investigators examined the place of death—out of hospital, outpatient, or inpatient—of children with asthma as the underlying cause of death between 2003 and 2014 from a national database. Outpatient deaths declined during the study period for Caucasian children, as did out-of-hospital deaths for African-American and Hispanic children. Inpatient deaths increased for all ethnic groups. However, African-American children were six times more likely to die from asthma than Hispanic or Caucasian children, and African-American children accounted for a significantly higher proportion of deaths than Caucasian children in all settings.
Predicting Hospital Readmission in COLD Patients
Data are lacking on early readmission rates among patients with chronic obstructive lung disease (COLD). As part of a study of hospital patients admitted with a primary diagnosis of asthma or COPD, collectively defined as COLD, researchers analyzed age- and mortality-adjusted comorbidities as risk factors for 30-day readmission. Among more than 5,700 COLD patients, 18.6% were readmitted within 30 days. Patients who were readmitted were significantly more likely to die during the study period (4.1% vs 2.7%, respectively). Chronic rhinitis was identified as the most significant predictor of 30-day readmission, followed by cardiac arrhythmia, obesity, anemia, tobacco use, and diabetes.
Bronchial Thermoplasty in High-Risk Asthma Patients
Previous research establishing the FDA approval of bronchial thermoplastly excluded high-risk asthma patients because of safety concerns. However, this patient population has higher levels of disease burden, fewer effective treatment options, and higher hospitalization rates when compared with asthma patients not excluded from this research. For a study, researchers examined treatment experiences of patients who did not meet inclusion criteria for bronchial thermoplastly. Nearly 100 patients underwent bronchial thermoplastly during general anesthesia or conscious sedation. Procedural complications occurred in just four patients and there were no cases of postoperative respiratory failure. Furthermore, only 28% of patients involved in the study experienced complications over the 6 weeks after treatment with bronchial thermoplastly.
Penicillin Allergy & Testing: Assessing Patient Awareness
Clinicians working in a general allergy clinic observed that although 25% of their patients had chart-reported penicillin allergy, penicillin testing was rarely performed in those who presented for non-drug allergy complaints. For a study, these clinicians created a one-page handout providing patient education about penicillin allergy and testing, with nurses providing the handout to all penicillin-allergic patients. An attached, five-question form assessed their prior knowledge of penicillin allergy and asked if they were interested in being tested. All patients who received the handout completed the survey. Among them, 70% did not know the allergy could be lost over time, 82% were not informed by their primary care provider that penicillin allergy testing was available, all expressed some interest in testing and found the handout useful, and 81% planned to or were scheduled for testing. Of 15 patients who underwent testing, 14 had negative skin testing results, tolerated an oral challenge, and were cleared of their allergy.
The Toll of Chronic Rhinosinusitis
Chronic rhinosinusitis is a highly prevalent, burdensome condition that has been linked to substantial healthcare utilization, but epidemiologic data derived from primary population sources are lacking. For a study, investigators collected information on more than 10,000 randomly sampled adults who participated in a population-based survey. Among those who fit the criteria for a chronic rhinosinusitis diagnosis with or without nasal polyps, 87% to 99% visited a doctor or took prescription medication (for nasal symptoms) in the prior 12 months. Despite available interventions, 41% with nasal polyps and 33% without remained “extremely” bothered by symptoms. More than half (54%) believed their symptoms were controlled, but 79% were concerned about flare-ups. Overall, 80% of survey respondents were frustrated by their inadequate symptom relief.
NEWS FROM AAAAI 2017
MORE FROM AAAAI 2017